$GTHX RESEARCH TRIANGLE PARK, N.C., March 31, 2022 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results of a retrospective, observational study describing the substantial burden of myelosuppression and its impact on healthcare resource utilization (HCRU) in 3,277 patients being treated with chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC). The study also described patient outcomes from 21 patients receiving trilaciclib prior to chemotherapy; of these, 17 received commercial trilaciclib in the real-world setting, and four received trilaciclib in clinical trials. Results showed that the use of trilaciclib prior to chemotherapy was associated with a 50% reduction in the percent of patients with grade ≥ 3 myelosuppressive hematologic adverse events (HAE) in at least one blood cell lineage and a 74% reduction in the percent of all-cause hospitalizations (days 1 to 21 after treatment), compared to patients who received chemotherapy alone. The analyses were derived using structured, real-world, de-identified clinical patient level data from the Integra Connect oncology warehouse. Findings are being presented in a poster session at the Annual Conference of the National Comprehensive Cancer Network (NCCN), held from March 31 to April 2, 2022
2
Нравится
Не является индивидуальной инвестиционной рекомендацией
4 комментария
Ваш комментарий...
31 марта 2022 в 20:17
Ура! На 20 центов отскочим! 🤑 (нет)
Нравится
31 марта 2022 в 20:17
Чё там на пиндостанком написано?
Нравится
1
31 марта 2022 в 20:19
@fabio11 копипаст в переводчик
Нравится
31 марта 2022 в 20:24
Что-то не видать ракеты на новостях. Только новое дно ловим.
Нравится